Literature DB >> 19582575

HER-2/neu and topoisomerase-II-alpha expression and genic amplification in pancreatic adenocarcinoma.

Gian Luca Baiocchi, Vincenzo Villanacci, Elisa Rossi, Federico Gheza, Nazario Portolani, Stefano M Giulini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19582575     DOI： 10.1007/s10620-009-0897-y

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  9 in total

1.  HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis.

Authors:  Evangelos Tsiambas; Andreas Karameris; Christos Dervenis; Andreas C Lazaris; Niki Giannakou; Kyriakos Gerontopoulos; Efstratios Patsouris
Journal:  JOP       Date:  2006-05-09

2.  A subset of pancreatic adenocarcinomas demonstrates coamplification of topoisomerase IIalpha and HER2/neu: use of immunolabeling and multicolor FISH for potential patient screening andtreatment.

Authors:  Donna E Hansel; Raheela Ashfaq; Ayman Rahman; Dana Wanzer; Charles J Yeo; Robb E Wilentz; Anirban Maitra
Journal:  Am J Clin Pathol       Date:  2005-01       Impact factor: 2.493

Review 3.  Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes--molecular basis for combination chemotherapy in cancer.

Authors:  Tero A H Järvinen; Edison T Liu
Journal:  Curr Cancer Drug Targets       Date:  2006-11       Impact factor: 3.428

Review 4.  Genetic alterations in pancreatic cancer.

Authors:  Muhammad Wasif Saif; Lena Karapanagiotou; Kostas Syrigos
Journal:  World J Gastroenterol       Date:  2007-09-07       Impact factor: 5.742

5.  Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.

Authors:  Matthew H Kulke; Lawrence S Blaszkowsky; David P Ryan; Jeffrey W Clark; Jeffrey A Meyerhardt; Andrew X Zhu; Peter C Enzinger; Eunice L Kwak; Alona Muzikansky; Colleen Lawrence; Charles S Fuchs
Journal:  J Clin Oncol       Date:  2007-10-20       Impact factor: 44.544

6.  HER2 gene amplification and chromosome 17 copy number do not predict survival of patients with resected pancreatic adenocarcinoma.

Authors:  Saima Sharif; Ramesh K Ramanathan; Douglas Potter; Kathleen Cieply; Alyssa M Krasinskas
Journal:  Dig Dis Sci       Date:  2008-05-08       Impact factor: 3.199

7.  Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas.

Authors:  Adrian M Senderowicz; John R Johnson; Rajeshwari Sridhara; Paul Zimmerman; Robert Justice; Richard Pazdur
Journal:  Oncology (Williston Park)       Date:  2007-12       Impact factor: 2.990

8.  Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms.

Authors:  J D Day; J A Digiuseppe; C Yeo; M Lai-Goldman; S M Anderson; S N Goodman; S E Kern; R H Hruban
Journal:  Hum Pathol       Date:  1996-02       Impact factor: 3.466

9.  Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis.

Authors:  Nhu-An Pham; Joerg Schwock; Vladimir Iakovlev; Greg Pond; David W Hedley; Ming-Sound Tsao
Journal:  BMC Cancer       Date:  2008-02-06       Impact factor: 4.430
  9 in total
  1 in total

1.  Cross-species comparison of orthologous gene expression in human bladder cancer and carcinogen-induced rodent models.

Authors:  Yan Lu; Pengyuan Liu; Weidong Wen; Clinton J Grubbs; Reid R Townsend; James P Malone; Ronald A Lubet; Ming You
Journal:  Am J Transl Res       Date:  2010-09-20       Impact factor: 4.060
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.